The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus

Who May Qualify: - 18 to 70 years of age; - Diagnosed as dilated cardiomyopathy. Specifically, (i) left ventricular ejection fraction \<45% (\>2 SD) and/or fractional shortening \<25% (\>2 SD), as ascertained by echocardiography, radionuclide scanning, or cardiac magnetic resonance imaging; (ii) left ventricular end-diastolic diameter \>117% of the predicted value corrected for age and body surface area (Henry's formula), which corresponds to 2 SD of the predicted normal limit +5%; and (iii) In the absence of severe coronary artery disease or valvular disease. - KSHV DNA seropositivity; - Patients are voluntary and signed willing to sign a consent form. Who Should NOT Join This Trial: - Allergic to rapamycin or its derivatives； - The proportion of neutrophils less than 0.5\*10\^9/L or platelet less than 2.5\*10\^10/L; - Pregnant women or plan to; - Participate in any drug clinical trials within 3 months; - Serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients); - Previous history of cancer or tumor, or pathological examination confirmed precancerous lesions; - Patients were not optimally managed. Always talk to your doctor about whether this trial is right for you.